Literature DB >> 3754599

1-Methyl-1,4-androstadiene-3,17-dione (SH 489): characterization of an irreversible inhibitor of estrogen biosynthesis.

D Henderson, G Norbisrath, U Kerb.   

Abstract

1-Methyl-1,4-androstadiene-3,17-dione (SH 489) was characterized as a competitive and irreversible inhibitor of human placental aromatase. The compound and the principal predicted metabolites show no endocrinological side effects suggesting that SH 489 should be suitable as a prototype drug for treatment of estrogen-dependent disease states.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3754599     DOI： 10.1016/0022-4731(86)90069-5

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN： 0022-4731            Impact factor:   4.292


  5 in total

Review 1.  Aromatase inhibitors--mechanisms of steroidal inhibitors.

Authors:  R W Brueggemeier
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 2.  Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.

Authors:  V Craig Jordan; Angela M H Brodie
Journal:  Steroids       Date:  2006-12-13       Impact factor: 2.668

3.  Inhibitors of aromatase prevent degradation of the enzyme in cultured human tumour cells.

Authors:  N Harada; O Hatano
Journal:  Br J Cancer       Date:  1998-02       Impact factor: 7.640

4.  A new irreversible aromatase inhibitor, 6-methylenandrosta-1,4-diene-3,17-dione (FCE 24304): antitumor activity and endocrine effects in rats with DMBA-induced mammary tumors.

Authors:  T Zaccheo; D Giudici; P Lombardi; E di Salle
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Metabolism of the steroidal aromatase inhibitor atamestane in rats, cynomolgus monkeys and humans. Isolation and identification of the major metabolites.

Authors:  W Kuhnz; G A Hoyer; S Backhus; U Jakobs
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Apr-Jun       Impact factor: 2.441
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.